4 results about "Polymyxin B Sulfate" patented technology

The application discloses a preparation method of polymyxin B sulfate impurity Z3 control product, and comprises the following steps: preparing a mobile phase, dissolving a sample containing polymyxin B sulfate, and then loading the sample into a chromatographic column, eluting the sample with the mobile phase, intercepting a fraction between a peak valley position of impurity B1-I and B1, and then re-loading and eluting the fraction to obtain a B1-I, Z3 and B1 triple peak after concentration, collecting a fraction corresponding to a peak part of Z3, repeatedly loading and eluting the fraction after concentration, and finally crystallizing to obtain a product Z3. The application has the advantages of simple operation, good separation effect and high-purity Z3 control product.

The application discloses a preparation method of a polymyxin B sulfate dry powder and belongs to the technical field of medicine preparation. The preparation of the polymyxin B sulfate dry powder is that the polymyxin B sulfate fermentation liquor is subjected to adsorption filtration by using a ZIF-8@polyurea / polyether sulfone composite membrane, and the filter cake is subjected to elution by using a sulfuric acid aqueous solution. The eluate is post-treated to obtain the polymyxin B sulfate dry powder. The application has the advantages of mild preparation condition, simple process, low reaction energy consumption and industrial application prospect.

The invention discloses an external antibacterial medicine composition as well as a preparation method and application thereof, and belongs to the technical field of antibacterial medicines. The external antibacterial pharmaceutical composition provided by the invention comprises a medicinal active component and a pharmaceutically acceptable carrier, wherein the medicinal active component comprises polymyxin B sulfate, trimethoprim sulfate and lidocaine; every 10 g of the antibacterial pharmaceutical composition for external use is prepared from the following components in parts by weight: 40000 to 60000 U of polymyxin B sulfate, 0.08 to 0.16 g of trimethoprim sulfate and 0.30 to 0.35 g of lidocaine. The pharmaceutical composition disclosed by the invention has broad-spectrum inhibition on multiple drug-resistant bacteria such as common gram-negative drug-resistant bacteria and acinetobacter baumannii on a wound surface, synchronously plays a synergistic role in relieving inflammatory response of the wound surface and relieving local pain, and remarkably improves the medication safety and the comprehensive treatment effect while ensuring excellent antibacterial activity.

This invention relates to a polymyxin inhalation liquid formulation and its preparation method, comprising 0.1-5% (w / v) polymyxin B sulfate, 0.05-1% (w / v) stabilizer, 0.1-0.9% (w / v) osmolarity regulator, pH adjuster, and solvent; the pH of the liquid formulation is 3.0-6.0; the solvent is selected from purified water and water for injection; the polymyxin inhalation solution provided by this invention has a simple composition, a pH of 3.0-6.0, and is osmotonic, which can reduce bronchospasm and cough caused by polymyxin inhalation solution. Safety evaluation has verified that it has good safety, providing a new option for clinical application.